U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16N4O
Molecular Weight 280.3244
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Y-33075

SMILES

C[C@@H](N)C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2

InChI

InChIKey=JTVBXQAYBIJXRP-SNVBAGLBSA-N
InChI=1S/C16H16N4O/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15/h2-10H,17H2,1H3,(H2,18,19,20,21)/t10-/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H16N4O
Molecular Weight 280.3244
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20434334 | https://www.ncbi.nlm.nih.gov/pubmed/24684843 | https://www.ncbi.nlm.nih.gov/pubmed/24008512 | https://www.ncbi.nlm.nih.gov/pubmed/21667088

Y-33075 is potent and selective ROCK (Rho-associated coiled-coil-forming protein kinase) inhibitor, developed by Yoshitomi Pharmaceutical Industries for encephalomyelitis treatment. In rabbits and in monkeys, Y-33075 lowers IOP in a dose-dependent fashion. An increase in regenerating axons of RGCs in 100 mM Y-33075-treated eyes is observed compared with saline-treated eyes. Y-33075 dose-dependently increases the number of RGCs with regenerating axons. Both Y-33075 induces a concentration-dependent relaxation in rabbit ciliary arteries precontracted with a high-potassium (high-K) solution. The amplitude of relaxation induced by Y-33075 is not affected by either 100 μM N (G)-nitro-L: -arginine methyl ester (L: -NAME) or 10 μM indomethacin. In Ca2 -free solution, Y-27632 and Y-39983 significantly inhibit the transient contraction of ciliary arteries induced by 10 μM histamine. However, neither Y-27632 nor Y-39983 affects the elevation of [Ca2 ](i) induced by high-K solution and histamine.

CNS Activity

Curator's Comment: Y-39983 is CNS active in animal model of multiple sclerosis. No human data available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
30.0 nM [IC50]
58.0 nM [IC50]
3.6 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes.
2005 Apr
Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys.
2007 Jul
Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells.
2011
Y-39983, a selective Rho-kinase inhibitor, attenuates experimental autoimmune encephalomyelitis via inhibition of demyelination.
2013
Patents

Sample Use Guides

Senju Pharmaceuticals completed a phase II trial that evaluated the dose-response relationship of ocular hypotensive efficacy and safety of Y 39983 at concentrations ranging from 0.003%, 0.01%, 0.03% or Y 39983 vehicle control given twice a day for 4 weeks in patients with primary open angle glaucoma or ocular hypertension (UMIN000018866)
Route of Administration: Topical
In medium containing 1 uM Y-39983, HUVECs exhibited contraction. The morphologic changes in HUVECs were reversible and had nearly recovered by 1 hour after removal of Y-39983
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:14:26 GMT 2023
Edited
by admin
on Fri Dec 15 16:14:26 GMT 2023
Record UNII
00ALI1GAY2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Y-33075
Common Name English
BENZAMIDE, 4-(1-AMINOETHYL)-N-1H-PYRROLO(2,3-B)PYRIDIN-4-YL-, (R)-
Systematic Name English
Y-39983 FREE BASE
Common Name English
Code System Code Type Description
CAS
199433-58-4
Created by admin on Fri Dec 15 16:14:26 GMT 2023 , Edited by admin on Fri Dec 15 16:14:26 GMT 2023
PRIMARY
FDA UNII
00ALI1GAY2
Created by admin on Fri Dec 15 16:14:26 GMT 2023 , Edited by admin on Fri Dec 15 16:14:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID50173718
Created by admin on Fri Dec 15 16:14:26 GMT 2023 , Edited by admin on Fri Dec 15 16:14:26 GMT 2023
PRIMARY
PUBCHEM
9810884
Created by admin on Fri Dec 15 16:14:26 GMT 2023 , Edited by admin on Fri Dec 15 16:14:26 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY